文献速递外周动脉疾病

肝素涂层支架移植物治疗TASC II C/D股腘病变:Viabahn 25 cm试验36个月结果

Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial.
PubMed 文献 · J Endovasc Ther · 2020-10-12

这项前瞻性多中心单臂试验纳入71例长段(>20 cm)股浅动脉和近端腘动脉TASC II C/D病变患者,评估25 cm Viabahn内置假体(Propaten生物活性表面)植入后36个月的技术和临床结局。主要终点36个月一期通畅率为40.6%,二期通畅率高达96.9%,无支架骨折发生。

要点

  • 长段股腘病变植入Viabahn后36个月一期通畅率仅40.6%,但二期通畅率达96.9%。
  • 36个月内27例需靶病变血运重建,无支架骨折发生。
  • 持续临床成功率(Rutherford分级稳定或改善)为58.5%。

核心结论

  • 长段股腘病变治疗后无再干预的一期通畅率低,但Viabahn植入后二期通畅率高,且临床改善持续。

研究设计与样本

  • 前瞻性、多中心、单臂试验(NCT01263665),纳入71例患者(平均年龄66.7±8.3岁,50例男性),病变为生活方式限制性跛行或静息痛(Rutherford 2-4级)且股浅动脉和近端腘动脉病变长度>20 cm。

主要发现

  • Kaplan-Meier估计36个月一期通畅率为40.6%。
  • 一期辅助通畅率和二期通畅率分别为53.0%和96.9%。
  • 36个月内27例患者需靶病变血运重建(TLR),25例(35.2%)发生靶血管血运重建(TVR)。
  • 无死亡、TVR和截肢复合终点的自由率为44.5%。
  • Rutherford分级稳定或改善的持续临床成功估计为58.5%,随访期间未检测到支架骨折。

关键数值与推荐

  • 主要终点为36个月一期通畅率,估计值为40.6%。
  • 次要终点包括一期辅助通畅率53.0%、二期通畅率96.9%、无TLR自由率(27例需TLR)、无死亡/TVR/截肢复合终点自由率44.5%、临床成功率58.5%和无支架骨折自由率(无骨折发生)。

临床怎么用

  • 对于长段股腘病变(TASC II C/D),Viabahn支架移植物可提供较高的二期通畅率和持续临床改善,但需注意一期通畅率较低且再干预率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the 36-month technical and clinical outcome after implantation of the 25-cm Viabahn endoprosthesis with Propaten bioactive surface in TransAtlantic Inter-Society Consensus II C and D lesions of the superficial femoral and proximal popliteal arteries. MATERIALS AND METHODS: This prospective, multicenter, single-arm trial (ClinicalTrials.gov; identifier NCT01263665) enrolled 71 patients (mean age 66.7±8.3 years; 50 men) with lifestyle-limiting claudication or rest pain (Rutherford category 2-4) and long (>20-cm) lesions of the superficial femoral and proximal popliteal arteries. Primary endpoint was primary patency at 36 months. Secondary endpoints included primary assisted patency; secondary patency; freedom from target lesion revascularization (TLR); freedom from a composite of death, target vessel revascularization (TVR), and amputation; clinical success; and freedom from device fracture. RESULTS: Primary patency estimated by Kaplan-Meier analysis was 40.6% at 36 months. Primary assisted patency and secondary patency estimates were 53.0% and 96.9%, respectively. Within 36 months, 27 patients had to undergo a TLR. Twenty-five patients (35.2%) had a TVR. Freedom from the composite of death, TVR, and amputation endpoint was 44.5%. The estimate of the sustained clinical success with stable or improved Rutherford category was 58.5%. No stent fracture was detected during follow-up. CONCLUSION: The primary patency rate without reintervention after treatment of long femoropopliteal lesions is low. However, secondary patency after implantation of a Viabahn endoprosthesis is high and seems to be superior to the use of other revascularization techniques, resulting in persistent clinical improvement.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Böhme T, Noory E, Brechtel K, et al. Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial. J Endovasc Ther. 2020. PMID: 33044119. doi:10.1177/1526602820965965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。